On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their October 2023 meeting. Actions in this consultation include:

  • Prednisolone enteric coated 2.5mg and 5mg tablets – remove from DNP list
  • Micronised progesterone 100mg capsules (Gepretix®) to be added to formulary for adjunctive use in postmenopausal women
  • Mavacamten added to formulary as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Monday 27th November 2023. To take part, visit the consultations page.